Table 1.
Summary of patient demographics and baseline characteristics by body weight and BMI
| Body weight | BMI | Total population (N = 936) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Categories | Thresholds | Categories | Thresholds | |||||||||
| ≤60 kg (N = 144) | > 60–75 kg (N = 319) | > 75–90 kg (N = 288) | > 90 kg (N = 185) | < 100 kg (N = 819) | ≥100 kg (N = 117) | ≤25 kg/m2 (N = 323) | > 25–30 kg/m2 (N = 330) | > 30 kg/m2 (N = 283) | < 36 kg/m2 (N = 844) | ≥36 kg/m2 (N = 92) | ||
| Female, n (%) | 125 (87) | 198 (62) | 149 (52) | 76 (41) | 499 (61) | 49 (42) | 188 (58) | 179 (54) | 181 (64) | 482 (57) | 66 (72) | 548 (59) |
| Mean (SD) age, years | 46.5 (18.7) | 51.5 (14.0) | 52.1 (12.0) | 50.1 (11.3) | 50.9 (14.2) | 48.9 (11.3) | 47.8 (16.4) | 53.1 (13.0) | 51.0 (11.0) | 50.9 (14.1) | 48.5 (11.7) | 50.6 (13.9) |
| Mean (SD) duration of asthma, years | 17.4 (12.1) | 20.3 (14.9) | 20.0 (14.5) | 20.0 (14.9) | 19.8 (14.4) | 18.9 (14.6) | 17.9 (13.8) | 20.1 (14.4) | 21.4 (14.9) | 19.4 (14.2) | 23.1 (15.4) | 19.7 (14.4) |
| Clinically significant exacerbations in the previous year, n (%) | ||||||||||||
| Mean (SD) | 3.4 (2.2) | 3.2 (2.7) | 3.0 (1.8) | 3.2 (2.2) | 3.2 (2.3) | 3.2 (2.2) | 3.2 (2.4) | 3.1 (2.2) | 3.2 (2.1) | 3.2 (2.3) | 3.3 (2.4) | 3.2 (2.3) |
| 2 | 72 (50) | 187 (59) | 171 (59) | 91 (49) | 464 (57) | 57 (49) | 181 (56) | 188 (57) | 152 (54) | 472 (56) | 49 (53) | 521 (56) |
| 3 | 28 (19) | 61 (19) | 52 (18) | 49 (26) | 160 (20) | 30 (26) | 60 (19) | 73 (22) | 57 (20) | 170 (20) | 20 (22) | 190 (20) |
| ≥ 4 | 44 (31) | 71 (22) | 65 (23) | 45 (24) | 195 (24) | 30 (26) | 82 (25) | 69 (21) | 74 (26) | 202 (24) | 23 (25) | 225 (24) |
| Receiving maintenance OCS therapy at baseline, n (%) | ||||||||||||
| Yes | 24 (17) | 80 (25) | 71 (25) | 52 (28) | 196 (24) | 31 (26) | 79 (24) | 74 (22) | 74 (26) | 204 (24) | 23 (25) | 227 (24) |
| No | 120 (83) | 239 (75) | 217 (75) | 133 (72) | 623 (76) | 86 (74) | 244 (76) | 256 (78) | 209 (74) | 640 (76) | 69 (75) | 709 (76) |
| Mean (SD) % predicted pre-bronchodilator FEV1 | 62.8 (16.8) | 59.4 (17.8) | 59.1 (15.8) | 57.7 (16.6) | 59.5 (16.8) | 59.4 (17.2) | 61.4 (17.7) | 58.7 (16.6) | 58.3 (16.1) | 59.7 (17.0) | 58.1 (15.7) | 59.5 (16.8) |
| Mean (SD) SGRQ total score | 45.5 (20.6) | 45.0 (18.6) | 47.7 (19.1) | 50.8 (17.5) | 46.6 (19.2) | 50.6 (17.1) | 43.9 (19.5) | 46.5 (18.5) | 51.4 (18.1) | 46.3 (19.0) | 53.7 (17.4) | 47.1 (18.9) |
| Mean (SD) ACQ-5 score | 2.2 (1.3) | 2.2 (1.1) | 2.1 (1.2) | 2.5 (1.2) | 2.2 (1.2) | 2.4 (1.1) | 2.2 (1.1) | 2.1 (1.2) | 2.4 (1.2) | 2.2 (1.2) | 2.5 (1.2) | 2.2 (1.2) |
| Geometric mean (SD of log) blood eosinophil count, cells/μL | 370 (1.13) | 320 (0.93) | 300 (0.90) | 360 (0.87) | 320 (0.96) | 360 (0.85) | 350 (0.98) | 310 (0.90) | 310 (0.96) | 320 (0.96) | 330 (0.81) | 330 (0.95) |
Percentages may not add up to 100, due to rounding
Abbreviations: ACQ Asthma Control Questionnaire, BMI Body mass index, FEV1 Forced expiratory volume in 1 s, OCS Oral corticosteroid, SD Standard deviation, SGRQ St George’s Respiratory Questionnaire